Sector: Health Care
Director information for ELANCO ANIMAL HEALTH INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Art Garcia | Former CFO, Ryder System, Inc.; Independent Director | 65 | ["Animal Health/Health Care Industry","Business Leadership and Operations","Digital, Technology and Cybersecurity","Finance and Accounting","Global Business Experience","Human Capital Management","Institutional Investor Perspective","M&A and Business Development","Public Company Board Experience","Risk Management and Sustainability","Business Leadership and Operations expertise acquired through his experience leading the finance organization at Ryder Systems","Finance and Accounting experience developed during the 18 years he served in financial roles at Ryder Systems","M&A and Business Development expertise obtained while overseeing the corporate strategy and business development functions","Institutional Investor Perspective developed through his nearly 10 years of experience engaging with the financial community"] | ["Audit","Finance","Strategy and Oversight"] | 2026 |
| Deborah Kochevar | Chair | [] | ["Innovation, Science and Technology Committee"] | 2026 | |
| Denise Scots-Knight | Co-Founder and CEO, Mereo BioPharma Group plc | 66 | ["Business Leadership and Operations","Finance and Accounting","Global Business Experience","Human Capital Management","Public Company Board Experience"] | ["Innovation, Science and Technology Committee"] | 2026 |
| Denise Scots-Knight, Ph.D | Co-Founder, Chief Executive Officer and Director | 66 | ["Health Care Industry experience acquired over her career in the life sciences industry","Global Business Experience gained through her service as Co-Founder and Chief Executive Officer of Mereo BioPharma","Institutional Investor Perspective obtained through her extensive experience investing and allocating capital as the head of a life sciences-focused venture capital firm","Research and Development/Innovation expertise developed through her career"] | ["Compensation and Human Capital","Innovation, Science and Technology"] | 2026 |
| Jeffrey Simmons | President and CEO, Elanco Animal Health Incorporated; President and Chief Executive Officer | 58 | ["Business Leadership and Operations","Finance and Accounting","Global Business Experience","Public Company Board Experience","Business Leadership and Operations expertise","M&A and Business Development experience","Risk Management and Sustainability expertise","Research and Development/Innovation experience"] | ["Finance","Strategy and Oversight"] | 2026 |
| Kapila Anand | Retired Partner, KPMG LLP | 72 | ["Animal Health/Health Care Industry","Business Leadership and Operations","Consumer Products","Finance and Accounting","Global Business Experience","Human Capital Management","M&A and Business Development","Public Company Board Experience","Risk Management and Sustainability","Finance and Accounting experience gained through her more than 30 years of services as a Certified Public Accountant at KPMG","Risk Management and Sustainability expertise developed over her career advising companies throughout their life cycle","Legal, Public Policy and Regulatory experience acquired while playing a leading role in the development of KPMG's private equity and regulatory businesses","M&A and Business Development experience obtained while acting as an advisory partner to KPMG's M&A and integration services practices"] | ["Audit","Corporate Governance"] | 2026 |
| Kirk McDonald | Founding Member and CEO, Sundial Media & Technology Group; Chief Executive Officer | 59 | ["Business Leadership and Operations","Consumer Products","Finance and Accounting","Global Business Experience","Human Capital Management","M&A and Business Development","Public Company Board Experience","Business Leadership and Operations expertise","Consumer Products experience","Digital, Technology and Cybersecurity expertise","Human Capital Management insights"] | ["Compensation and Human Capital","Innovation, Science and Technology"] | 2026 |
| Lawrence Kurzius | Former Executive Chairman, McCormick & Company, Inc. | 68 | ["Animal Health/Health Care Industry","Business Leadership and Operations","Finance and Accounting","Global Business Experience","Human Capital Management","M&A and Business Development","Public Company Board Experience","Risk Management and Sustainability","Consumer Products experience acquired over his career in consumer goods marketing and senior leadership roles at Mars, Quaker Oats, Zatarain’s and McCormick","Global Business Experience gained leading multinational companies, where understanding both the domestic and international markets was essential to success","Human Capital Management expertise developed through his leadership of a company with over 14,000 employees globally","Risk Management and Sustainability experience obtained from his broad executive experience at McCormick"] | [] | 2026 |
| Michael Harrington | Former General Counsel, Eli Lilly and Company ("Lilly"); Independent Director; Chairman of the Board | 63 | ["Animal Health/Health Care Industry","Business Leadership and Operations","Consumer Products","Finance and Accounting","Global Business Experience","Human Capital Management","Institutional Investor Perspective","Legal, Public Policy and Regulatory","M&A and Business Development","Public Company Board Experience","Risk Management and Sustainability","Animal Health/Health Care Industry experience in more than three decades at Lilly","Digital, Technology and Cybersecurity expertise","Legal, Public Policy and Regulatory expertise","M&A and Business Development expertise"] | ["Audit","Corporate Governance (Chair)","Finance","Strategy and Oversight","Corporate Governance Committee"] | 2026 |
| Paul Herendeen | Former CFO, Bausch Health Companies, Inc.; Independent Director; Chair | 70 | ["Animal Health/Health Care Industry","Business Leadership and Operations","Consumer Products","Finance and Accounting","Global Business Experience","Human Capital Management","M&A and Business Development","Public Company Board Experience","Risk Management and Sustainability","More than 20 years’ experience serving in leadership positions at MedPointe, Warner Chilcott, Zoetis, and Bausch Health","Finance and Accounting expertise developed through decades serving in financial roles in the life sciences industry","M&A and Business Development experience from his tenure at Warner Chilcott, MedPointe, Zoetis and Bausch Health","Institutional Investor Perspective developed through more than 15 years of experience engaging with the financial community"] | ["Audit","Finance","Strategy and Oversight"] | 2026 |
| R. David Hoover | [] | [] | 2026 | ||
| Stacey Ma | Executive Vice President, Gilead Sciences, Inc. | 56 | ["Business Leadership and Operations","Digital, Technology and Cybersecurity","Finance and Accounting","Global Business Experience","Human Capital Management","M&A and Business Development","Public Company Board Experience"] | [] | 2026 |
| Stacey Ma, Ph.D | Executive Vice President of Pharmaceutical Development and Manufacturing | 56 | ["Animal Health/Health Care Industry experience gained through nearly 30 years","Business Leadership and Operations leader with extensive experience in product and supply chain management, manufacturing, and quality operations","Research and Development/Innovation expertise developed by leading technology innovation and product development","Elected to the National Academy of Engineering in 2026","Legal, Public Policy, and Regulatory experience gained through leadership of CMC regulatory functions"] | ["Compensation and Human Capital","Innovation, Science and Technology"] | 2026 |
